A semi-naturalistic open-label study examining the effect of prescribed medical cannabis use on simulated driving performance
Journal of Psychopharmacology · 2024
DOI: 10.1177/02698811241229524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Psychopharmacology, 2024. Verfasst von Brooke Manning und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Mental Health and Brain Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia. Hauptthemen laut MEDLINE: Medical Marijuana, Hallucinogens, Cannabis, Automobile Driving. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: rebecca l. cooper medical research foundation, National Health and Medical Research Council.
Abstract (Originalsprache)
Background
Despite increasing medical cannabis use, research has yet to establish whether and to what extent products containing delta-9-tetrahydrocannabinol (THC) impact driving performance among patients. Stable doses of prescribed cannabinoid products during long-term treatment may alleviate clinical symptoms affecting cognitive and psychomotor performance.
Aim
To examine the effects of open-label prescribed medical cannabis use on simulated driving performance among patients.
Methods
In a semi-naturalistic laboratory study, 40 adults (55% male) aged between 23 and 80 years, consumed their own prescribed medical cannabis product. Driving performance outcomes including standard deviation of lateral position (SDLP), the standard deviation of speed (SDS), mean speed and steering variability were evaluated using the Forum8 driving simulator at baseline (pre-dosing), 2.5 h and 5 -h (post-dosing). Perceived driving effort (PDE) was self-reported after each drive. Oral fluid and whole blood samples were collected at multiple timepoints and analysed for THC via liquid chromatography-mass spectrometry.
Results
A significant main effect of time was observed for mean speed (p = 0.014) and PDE (p = 0.020), with patients displaying modest stabilisation of vehicle control, increased adherence to speed limits and reductions in PDE post-dosing, relative to baseline. SDLP (p = 0.015) and PDE (p = 0.043) were elevated for those who consumed oil relative to flower-based products. Detectable THC concentrations were observed in oral fluid at 6-h post-dosing (range = 0–24 ng/mL).
Conclusions
This semi-naturalistic study suggests that the consumption of medical cannabis containing THC (1.13–39.18 mg/dose) has a negligible impact on driving performance when used as prescribed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Mental Health and Brain Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia.
- Institute for Breathing and Sleep (IBAS), Austin Health, Melbourne, VIC, Australia.
ORCID-Profile: Brooke Manning, Amie C Hayley
Förderung
- rebecca l. cooper medical research foundation
- National Health and Medical Research Council
Zitieren
APA
Manning, B., Arkell, T. R., Hayley, A. C., & Downey, L. A. (2024). A semi-naturalistic open-label study examining the effect of prescribed medical cannabis use on simulated driving performance. Journal of Psychopharmacology. https://doi.org/10.1177/02698811241229524
Vancouver
Manning B, Arkell TR, Hayley AC, Downey LA. A semi-naturalistic open-label study examining the effect of prescribed medical cannabis use on simulated driving performance. Journal of Psychopharmacology. 2024. doi:10.1177/02698811241229524
BibTeX
@article{Manning2024,
author = {Manning, Brooke and Arkell, Thomas R and Hayley, Amie C and Downey, Luke A},
title = {A semi-naturalistic open-label study examining the effect of prescribed medical cannabis use on simulated driving performance},
journal = {Journal of Psychopharmacology},
year = {2024},
doi = {10.1177/02698811241229524}
}
EUVIMED